Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$74.24
Market cap
$11.77B
P/E Ratio
69.38
Dividend/share
$0.32
EPS
$1.07
Enterprise value
$12.04B
Bio-Techne Corporation is a holding company for biotechnology and clinical diagnostic brands. It was founded in 1976 as Techne Corporation and changed its name to Bio-Techne in 2014. The company's
Highlights
BIO-TECHNE's debt has decreased by 15% QoQ and by 8% YoY
BIO-TECHNE's equity has increased by 5% YoY and by 2.7% from the previous quarter
The net income has decreased by 41% YoY and by 17% from the previous quarter
TECH's EPS is down by 41% year-on-year and by 16% since the previous quarter
Key stats
What are the main financial stats of TECH
Market
Valuations
Earnings
Shares outstanding
158.6M
Market cap
$11.77B
Enterprise value
$12.04B
Price to earnings (P/E)
69.38
Price to book (P/B)
5.65
Price to sales (P/S)
10.1
EV/EBIT
59.79
EV/EBITDA
38.46
EV/Sales
10.39
Revenue
$1.16B
EBIT
$201.43M
EBITDA
$313.14M
Free cash flow
$236.1M
Per share
Balance sheet
Liquidity
EPS
$1.07
Free cash flow per share
$1.5
Book value per share
$13.13
Revenue per share
$7.35
TBVPS
$7.76
Total assets
$2.7B
Total liabilities
$635.02M
Debt
$419.54M
Equity
$2.07B
Working capital
$458.04M
Debt to equity
0.2
Current ratio
3.87
Quick ratio
2.47
Net debt/EBITDA
0.86
Margins
Efficiency
Dividend
EBITDA margin
27%
Gross margin
66.4%
Net margin
14.5%
Operating margin
17.8%
Return on assets
6.2%
Return on equity
8.4%
Return on invested capital
14.1%
Return on capital employed
7.9%
Return on sales
17.4%
Dividend yield
0.43%
DPS
$0.32
Payout ratio
29.9%
TECH stock price
How has the BIO-TECHNE stock price performed over time
Intraday
4.95%
1 week
7.07%
1 month
-7.12%
1 year
31.07%
YTD
-3.78%
QTD
-7.12%
Financial performance
How have BIO-TECHNE's revenue and profit performed over time
Revenue
$1.16B
Gross profit
$769.73M
Operating income
$206.69M
Net income
$168.11M
Gross margin
66.4%
Net margin
14.5%
BIO-TECHNE's net margin has decreased by 42% YoY and by 18% QoQ
The net income has decreased by 41% YoY and by 17% from the previous quarter
BIO-TECHNE's operating margin has decreased by 32% YoY and by 19% QoQ
The company's operating income fell by 31% YoY and by 19% QoQ
Growth
What is BIO-TECHNE's growth rate over time
Valuation
What is BIO-TECHNE stock price valuation
P/E
69.38
P/B
5.65
P/S
10.1
EV/EBIT
59.79
EV/EBITDA
38.46
EV/Sales
10.39
TECH's EPS is down by 41% year-on-year and by 16% since the previous quarter
TECH's P/E is 20% above its last 4 quarters average of 55.2 and 8% above its 5-year quarterly average of 61.1
The stock's price to book (P/B) is 29% less than its 5-year quarterly average of 7.6 and 3.8% less than its last 4 quarters average of 5.6
BIO-TECHNE's equity has increased by 5% YoY and by 2.7% from the previous quarter
The price to sales (P/S) is 27% lower than the 5-year quarterly average of 13.1
Efficiency
How efficient is BIO-TECHNE business performance
BIO-TECHNE's ROIC has plunged by 53% YoY and by 17% from the previous quarter
TECH's return on assets is down by 46% year-on-year and by 17% since the previous quarter
BIO-TECHNE's return on equity has decreased by 45% YoY and by 18% QoQ
TECH's return on sales is down by 44% year-on-year and by 18% since the previous quarter
Dividends
What is TECH's dividend history
DPS
$0.32
Dividend yield
0.43%
Payout ratio
29.9%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did BIO-TECHNE financials performed over time
The quick ratio has declined by 25% year-on-year
TECH's current ratio is down by 20% YoY and by 5% from the previous quarter
BIO-TECHNE's debt is 80% lower than its equity
TECH's debt to equity is down by 20% since the previous quarter and by 13% year-on-year
BIO-TECHNE's debt has decreased by 15% QoQ and by 8% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.